Remimazolam features: which statement is true?

Remimazolam features: which statement is true?

• A. Long-lasting with hepatic metabolism
• B. Active metabolites responsible for prolonged effects
• C. Ultrashort-acting benzodiazepine rapidly metabolized by non-specific plasma esterases
• D. Not used in anesthesia

Answer: (C)

Remimazolam is an ultrashort-acting benzodiazepine because it is rapidly inactivated in the blood by non-specific plasma esterases, not by hepatic enzymes. This metabolic pathway produces an inactive metabolite and yields a very quick offset of effect, allowing rapid recovery after dosing and making organ dysfunction less of a concern for duration. That’s why the statement describing it as ultrashort-acting and rapidly metabolized by non-specific plasma esterases is true. In contrast, claims of long-lasting action due to hepatic metabolism or effects driven by active metabolites don’t fit its pharmacokinetics, and saying it’s not used in anesthesia is simply incorrect because it is used for induction and sedation.

Remimazolam is an ultrashort-acting benzodiazepine because it is rapidly inactivated in the blood by non-specific plasma esterases, not by hepatic enzymes. This metabolic pathway produces an inactive metabolite and yields a very quick offset of effect, allowing rapid recovery after dosing and making organ dysfunction less of a concern for duration. That’s why the statement describing it as ultrashort-acting and rapidly metabolized by non-specific plasma esterases is true. In contrast, claims of long-lasting action due to hepatic metabolism or effects driven by active metabolites don’t fit its pharmacokinetics, and saying it’s not used in anesthesia is simply incorrect because it is used for induction and sedation.